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Articles
Mannose-binding lectin deﬁ ciency and disease severity in 
non-cystic ﬁ brosis bronchiectasis: a prospective study
James D Chalmers, Brian J McHugh, Catherine Doherty, Maeve P Smith, John R Govan, David C Kilpatrick, Adam T Hill
Summary
Background Mannose-binding lectin (MBL) is a key component of innate immunity. MBL deﬁ ciency is common 
(10–30% of the general population depending on the deﬁ nition used) and has been associated with disease 
progression in cystic ﬁ brosis. We aimed to assess the eﬀ ect of MBL deﬁ ciency on disease severity in non-cystic 
ﬁ brosis bronchiectasis.
Methods We recruited patients with non-cystic ﬁ brosis bronchiectasis and age-matched and sex-matched controls at a 
specialist bronchiectasis clinic in Edinburgh, UK. We assessed MBL function with genotyping (low-expressing 
genotype [deﬁ ciency] deﬁ ned as homozygosity for exon 1 mutations [YO/YO] or compound heterozygosity [XA/YO]; 
YA/YO and XA/XA genotypes were deﬁ ned as intermediate-expressing with all other genotypes deﬁ ned as high-
expressing) and serum measurements (deﬁ ciency deﬁ ned with two parameters: <500 ng/mL or <200 ng/mL). We 
assessed rates of exacerbation, chronic bacterial colonisation, and lung function during 4 years of follow-up.
Findings We included 470 patients with bronchiectasis and 414 controls. MBL genotype frequencies and MBL 
serum concentrations did not diﬀ er between patients and controls. 55 (12%) patients with bronchiectasis had low-
expressing genotypes. These patients had a mean of 2·7 exacerbations per year (SD 1·8), compared with 1·9 per 
year (1·2) for 135 patients with intermediate-expressing genotypes and 1·9 per year (1·3) for 280 patients with 
high-expressing genotypes (p<0·0001). Chronic colonisation with bacteria was most frequent in patients with 
low-expressing genotypes (47 [85%] patients vs 82 [61%] patients with intermediate-expressing genotypes and 
183 [65%] patients with high-expressing genotypes; p=0·0041); especially P aeruginosa colonisation (19 [35%] 
patients vs 13 [10%] patients and 36 [13%] patients; p<0·0001). Patients with low-expressing genotypes were more 
likely to be admitted to hospital for severe exacerbations during follow-up (27 [49%] patients vs 42 [31%] patients 
and 87 [31%] patients; p=0·032). Patients with low-expressing genotypes also had increased scores for radiological 
severity and worse quality of life compared with the other two groups. MBL serum deﬁ ciency (<200 ng/mL) was 
associated with increased exacerbations, hospital admissions, and radiological severity. When <500 ng/mL was 
used as the deﬁ nition of deﬁ ciency, the associations with exacerbation frequency and radiological severity were no 
longer signiﬁ cant.
Interpretation MBL might be an important modiﬁ er of disease severity in non-CF bronchiectasis.
Funding UK Medical Research Council, UK Chief Scientists Oﬃ  ce.
Introduction
Bronchiectasis is a chronic inﬂ ammatory lung disease 
characterised by permanent dilatation of the bronchi.1 
Patients with the disease have daily cough, sputum 
production, and recurrent respiratory infections.1 Central 
to the pathogenesis of bronchiectasis is a cycle of failed 
bacterial clearance, airway inﬂ ammation, and airway 
structural damage.2 Patients become chronically col-
onised with pathogens owing to a failure of host immune 
defences.3 The cause of adult bronchiectasis for most 
patients is unknown.4
Mannose-binding lectin (MBL) is a soluble pattern-
recognition molecule of the innate immune system.5 
MBL binds to glycoconjugates containing mannose, 
fucose or N-acetylglucosamine on the surface of a wide 
range of clinically important bacteria, viruses and fungi, 
activating the lectin pathway of com plement.6,7 Through 
complement activation, MBL promotes phagocytosis and 
leucocyte chemotaxis and activation.8,9 MBL might also 
have a role in the resolution of inﬂ ammation in the lung 
through the clearance of apoptotic cells and in 
suppression of proinﬂ ammatory cytokine secretion.10,11
MBL deﬁ ciency is one of the most common immune 
defects, aﬀ ecting 10–30% of people depending on the 
deﬁ nition of deﬁ ciency used.12 MBL deﬁ ciency has been 
associated with recurrent respiratory infections, and is 
associated with the presence of bronchiectasis in patients 
with common variable immunodeﬁ ciency.13
Although MBL deﬁ ciency is not the cause of cystic 
ﬁ brosis, several studies have shown that such a status 
modiﬁ es the course of disease in cystic ﬁ brosis, leading 
to a more rapid decline in forced expiratory volume in 1 s 
(FEV1), early acquisition of Pseudomonas aeruginosa, 
infection with Burkholderia cepacia, and death.14–16 In this 
study, we aimed to assess whether mannose-binding 
lectin deﬁ ciency was also associated with disease severity 
and clinical outcomes in adults with non-cystic ﬁ brosis 
bronchiectasis.
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Methods
Study design and patients
We recruited patients with non-cystic ﬁ brosis bron-
chiectasis from a regional specialist bronchiectasis 
clinic at the Royal Inﬁ rmary of Edinburgh (Edinburgh, 
UK). Bronchiectasis was deﬁ ned as presence of 
bronchial dilatation on high-resolution CT scanning 
with a compatible clinical history of daily cough with 
sputum production and recurrent respiratory infections.
We excluded patients with primary immunodeﬁ ciency 
(eg, common variable immunodeﬁ ciency), active malig-
nant disease, cystic ﬁ brosis, active allergic broncho-
pulmonary aspergillosis (as deﬁ ned elsewhere;4 current 
treatment with corticosteroids or itraconazole was also 
an exclusion), interstitial lung disease, active myco-
bacterial disease, current smoking (within 2 years), HIV 
infection, or current chronic liver disease.
We recruited age-matched and sex-matched healthy 
volunteers from the spouses and partners of patients 
attending the outpatient clinics at the Royal Inﬁ rmary of 
Edinburgh.
The study was approved by the local research ethics 
committee and all participants provided written in-
formed consent.
Procedures
At the time of inclusion, all patients were clinically stable 
with no antibiotic use in the preceding 4 weeks. We 
followed up patients for 4 years with review every 
6 months. Patients provided blood samples for genomic 
DNA extractions, serum for measurement of MBL, and 
spontaneous sputum samples for bacteriological analysis 
and markers of airway inﬂ ammation.
We assessed severity of bronchiectasis by scoring high-
resolution CT scans with a modiﬁ ed Reiﬀ  score.4,17 At every 
visit, all patients underwent clinical assessments including 
spirometry FEV1, forced vital capacity with the highest of 
three technically satisfactory measurements re corded),18 
and chest radio graphy. Patients completed the St George’s 
respiratory questionnaire (minimum clin ically important 
diﬀ erence 4 units)19 and the Leicester cough questionnaire 
(minimum clinically important diﬀ erence 1·3 units)20 as 
measures of quality of life and cough severity.
We recorded unscheduled hospital admissions in the 
previous year for severe exacerbations from patient 
histories and veriﬁ ed reports by use of an administrative 
database that recorded all regional hospital admissions. 
We quantiﬁ ed outpatient antibiotic use for exacerbations 
of bronchiectasis from patient histories and veriﬁ ed 
ﬁ ndings against primary-care prescription records. Such 
clinical databases are widely used in clinical research in 
the UK.21 We classiﬁ ed patients as chronically colonised if 
they isolated in sputum culture a potentially pathogenic 
microorganism on two occasions at least 3 months apart 
in 1 year while clinically stable.
We undertook quantitative and qualitative bacterio-
logical analysis as previously described.22 For measure-
ment of markers of airway inﬂ ammation, sputum was 
ultracentrifuged at 50 000 × g for 90 min at 4°C. The sol 
phase was removed and immediately frozen at –70°C. We 
measured markers of airway inﬂ ammation as previously 
described.23
We did serum measurement of MBL as described 
elsewhere.24 Brieﬂ y, diluted sera were incubated in 
mannan-coated ELISA plates and bound MBL was 
detected with a speciﬁ c monoclonal antibody to MBL 
(HYB131-01) followed by anti-mouse immunoglobulin 
conjugated to alkaline phosphatase with p-nitrophenyl 
phosphate as a substrate. Previous validation of this 
Abbreviated 
genotype
Abbreviated 
combined 
genotypes
MBL 
expression
HYPD/LYQC/LYPB haplotype O YO/YO Low
LXPA haplotype XA XA/YO Low
LYPA/LYQA haplotype YA YA/YO Intermediate
HYPA haplotype
Type 1 YA XA/XA Intermediate
Type 2 YA YA/XA High
Type 3 YA YA/YA High
MBL=mannose-binding lectin.
Table 1: Haplotypes and abbreviated genotypes according to serum 
MBL expression
55 low-expressing genotype 135 intermediate-expressing genotype
55 completed 4 years’ follow-up
    8 died
135 completed 4 years’ follow-up
      10 died
280 high-expressing genotype
280 completed 4 years’ follow-up
      24 died
583 patients with HRCT-conﬁrmed
         bronchiectasis screened
113 excluded
        12 active malignant disease
          2 known immunodeﬁciency
          6 active ABPA
        15 interstitial lung disease
          5 active mycobacterial disease
       42 current smoking
          3 chronic liver disease
          1 HIV
          5 long-term corticosteroid use
          3 long-term antibiotic use
          8 declined to participate
        10 not able to consent
          1 cystic ﬁbrosis
470 consented to be included
470 genotyped
Figure 1: Trial proﬁ le
HRCT=high-resolution CT. ABPA=allergic bronchopulmonary aspergillosis.
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assay showed an intra-assay coeﬃ  cient of variation of 
3·5% and inter-assay coeﬃ  cient of variation of 7%.24
To assess the eﬀ ects of changes in MBL on disease 
severity over time, we measured serum MBL at study 
baseline, midpoint, and at the end of the study in all 
patients. In addition, to determine the eﬀ ect of 
exacerbations on serum MBL, we recruited 68 patients 
attending the Royal Inﬁ rmary of Edinburgh 
bronchiectasis service for treatment of exacerbations.23 
Serum samples were obtained at day 1 (start of 
exacerbation) and day 14 (end of exacerbation). We 
treated patients with intravenous antibiotic therapy on 
the basis of their previous sputum microbiological 
results for 14 days. Repeat measurements were then 
made at least 3 months after exacerbation to determine 
return of MBL concentrations to baseline levels.
Genomic DNA was isolated from EDTA (edetic acid)-
anticoagulated whole-blood samples with the Nucleon 
BACC-3 kit (Gen-Probe, MA, USA). Isolated DNA was 
quality-tested and genotyping was done at the Wellcome 
Trust Clinical Research Facility Genetics Core 
(Edinburgh, UK). Validated Taqman allele speciﬁ c PCR 
primers were purchased from Applied Biosystems (CA, 
USA) and PCR done on the Applied Biosystems 7900HT 
according the manufacturer’s instructions. We studied 
six single-nucleotide polymorphisms (SNPs) known to 
have the greatest eﬀ ect on MBL serum concentrations: 
the exon-1 polymorphisms B-rs1800450, C-rs1800451, 
and D-rs5030737, the promoter polymorphisms H/L, 
rs11003125, X/Y, and rs7096206, and the 5′-untranslated 
region SNP P/Q, rs7095891. These SNPs comprise 
seven well-characterised “secretor haplotypes” (HYPA, 
LYPA, LYQA, LXPA, HYPD, LYPB, and LYQC) which 
strongly inﬂ uence circulating MBL concentrations24 
(table 1).
No universally agreed upon deﬁ nition of MBL 
deﬁ ciency exists. MBL function can be assessed by 
genotype, serum concentrations, or functional activity in 
complement activation assays. Although these assess-
ments are strongly correlated, they do not provide 
identical results. To account for this, we present data with 
three deﬁ nitions of MBL deﬁ ciency determined a priori 
as genotypes associated with MBL deﬁ ciency, serum 
concentrations of less than 500 ng/mL, and serum 
concentrations of less than 200 ng/mL.
Statistical analysis
Normally distributed data are presented as mean (SD) 
and non-normally distributed data are presented as 
median (IQR). We analysed deviation from the normal 
distribution with the D’Agostino and Pearson omnibus 
K² test. For comparisons of more than two groups of 
continuous data, we used one-way ANOVA or the 
Kruskal-Wallis test as appropriate. We used the χ² test to 
analyse more than two groups of categorical data. To 
adjust for confounders of the relation between MBL 
deﬁ ciency and chronic colonisation, we used multi-
variable logistic regression analysis. To investigate the 
relation between MBL genotype and survival, we used 
the Cox’s proportional hazard model to estimate 
survivor functions with survival during 4 years of follow-
up as the dependent variable. We adjusted for variables 
associated with mortality (p<0·05) in univariate 
analysis. For all analyses, p<0·05 was regarded as 
signiﬁ cant. Analyses were done with SPSS version 21 
and Graphpad Prism software.
Role of the funding source
The sponsor of the study had no role in study design, 
data collection, data analysis, data interpretation, or 
writing of the report. The corresponding author had full 
access to all the data in the study and had ﬁ nal 
responsibility for the decision to submit for publication.
Results
We included 470 patients with non-cystic ﬁ brosis 
bronchiectasis and 414 healthy controls (ﬁ gure 1). No 
patients were lost to follow-up. Table 2 shows the 
characteristics of the study population. None of the 
patients included in the study was treated with long-
term (>28 days) oral or nebulised antibiotics or oral 
corticosteroids. We noted no signiﬁ cant diﬀ erences in 
demographics or non-respiratory comorbid illnesses 
between patients with bronchiectasis and controls. In 
addition to a diagnosis of bronchiectasis, 55 patients 
had previously been diagnosed with asthma and 
17 patients had chronic obstructive pulmonary disease. 
Bronchiectasis 
cohort 
(n=470)
Control 
cohort 
(n=414)
p value
Age, years 64 (53–72) 65 (53–74) 0·22
Sex, female 259 (55%) 211 (51%) 0·22
Body-mass index, kg/m² 25·4 (5·2) Not recorded ··
Ex-smokers 177 (38%) 180 (43%) 0·079
Comorbidities
Chronic cardiac disease 108 (23%) 99 (24%) 0·74
Cerebrovascular disease 46 (10%) 42 (10%) 0·86
Chronic renal impairment 32 (7%) 33 (8%) 0·51
Diabetes mellitus 58 (12%) 41 (10%) 0·25
COPD 17 (4%) 0 <0·0001
Asthma 55 (12%) 0 <0·0001
Cause of bronchiectasis
Idiopathic or after infection 378 (80%) ·· ··
Previous ABPA 41 (9%) ·· ··
Connective tissue disease 28 (6%) ·· ··
Inﬂ ammatory bowel disease 14 (3%) ·· ··
Others 9 (2%) ·· ··
Inhaled corticosteroid use 196 (42%) 0 <0·0001
Data are median, n (%), or mean (SD). COPD=chronic obstructive pulmonary 
disease. ABPA=allergic bronchopulmonary aspergillosis.
Table 2: Clinical characteristics of the study population
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378 (80%) of 470 patients had idiopathic or post-infective 
bronchi ectasis. No controls had a history of chronic 
respiratory disease and none had been prescribed 
inhaled cortico steroids (table 2).
All studied SNPs were in Hardy-Weinberg equilibrium 
(p>0·05). Patients with high-expressing genotypes had a 
mean serum MBL concentration of 2300 ng/mL 
(SD 1300), compared with 950 ng/mL (SD 870) with 
inter mediate-expressing genotypes, and 130 ng/mL (SD 
220) in patients with low-expressing genotypes (deﬁ ned 
as MBL deﬁ cient).
Genotype frequencies and serum MBL concentrations 
did not diﬀ er between patients with bronchiectasis and 
controls (table 3). The frequency of MBL deﬁ ciency did 
not vary according to cause of bronchiectasis (data not 
shown).
361 (77%) of 470 patients had chronic bacterial colon-
isation. Haemophilus inﬂ uenzae was the most frequently 
isolated pathogen (141 patients [30%]), followed by 
P aeruginosa (68 patients [14%]), Moraxella catarrhalis 
(54 patients [11%]), enteric gram-negative organisms 
(46 patients [10%]), Staphylococcus aureus (43 patients 
[9%]), and Streptococcus pneumoniae (30 patients [6%]).
We noted a higher frequency of bacterial colonisation 
for patients with low-expressing genotypes (table 4) and 
deﬁ ciency for both serum concentrations (table 5). Rates 
of bacterial colonisation did not diﬀ er between patients 
with intermediate-expressing geno types and those with 
high-expressing genotypes (p=0·36). For both serum 
concentration cutoﬀ s, we noted a higher frequency of 
bacterial colonisation with H inﬂ uenzae, and P aeruginosa 
in the MBL-deﬁ cient group than in the non-deﬁ cient 
group. However, this eﬀ ect was not evident when 
patients with the low-expressing genotype were 
excluded, suggesting that this diﬀ erence was wholly 
attributable to these patients. After adjustment for age, 
radiographic severity, and percentage predicted FEV1, 
the logistic regression analysis did not show a signiﬁ cant 
eﬀ ect of low-expressing genotypes on chronic colon-
isation (adjusted odds ratio 1·85, 95% CI 0·96–3·59; 
p=0·063). The relation between low-expressing geno-
types and P aeruginosa was not signiﬁ cant after adjust-
ment for age, radiographic severity, and percentage 
predicted FEV1 (1·25, 0·55–2·83; p=0·65).
Rates of colonisation with other bacterial species did 
not correlate with MBL deﬁ ciency as deﬁ ned by genotype, 
although the numbers of cases in each group were small. 
One patient was chronically colonised with B cepacia and 
this patient had YO/YO genotype.
MBL deﬁ ciency deﬁ ned by genotype or serum 
concentration was not related to percentage predicted 
FEV1 or FVC (tables 4, 5). Patients with the low-
expressing genotype had more severe radiological 
bronchiectasis with the modiﬁ ed Reiﬀ  score (table 4), as 
did patients with serum deﬁ ciency deﬁ ned as less than 
200 ng/mL (table 5). This eﬀ ect was not evident when 
serum deﬁ ciency was deﬁ ned as less than 500 ng/mL. 
Pul monary function did not diﬀ er between patients 
with intermediate-expressing and high-expressing 
geno types.
Frequency of exacerbations in the year before the study 
was higher in the low-expressing genotype group than it 
Bronchiectasis 
cohort 
(n=470)
Control 
cohort 
(n=414)
p value
Low-expressing groups 55 (12%) 42 (10%) 0·46
YO/YO 18 (4%) 14 (3%) 0·72
XA/YO 37 (8%) 28 (7%) 0·53
Intermediate-expressing groups 135 (29%) 145 (35%) 0·06
YA/YO 111 (24%) 117 (28%) 0·12
XA/XA 24 (5%) 28 (7%) 0·30
High-expressing groups 280 (60%) 227 (55%) 0·15
YA/XA 119 (25%) 95 (23%) 0·41
YA/YA 161 (34%) 132 (32%) 0·45
Serum levels
<500 ng/mL 128 (27%) 122 (29%) 0·46
<200 ng/mL 88 (19%) 79 (19%) 0·89
Data are n (%). MBL=mannose-binding lectin.
Table 3: Genotype frequencies and serum concentrations in patients 
with non-cystic ﬁ brosis bronchiectasis and controls
 Low-expressing 
group (n=55)
Intermediate-
expressing 
group (n=135)
High-expressing 
group (n=280)
p value
Age, years 63 (53–70) 65 (55–71) 63 (52–72) 0·96
Bacteriological ﬁ ndings
Chronic colonisation 47 (85%) 82 (61%) 183 (65%) 0·0041
Haemophilus inﬂ uenzae 26 (47%) 36 (27%) 79 (28%) 0·011
Pseudomonas aeruginosa 19 (35%) 13 (10%) 36 (13%) <0·0001
Pulmonary function
FEV1, percentage predicted 68·9% (25·5) 70·0% (24·4) 74·3% (24·8) 0·096
FVC, percentage predicted 81·6% (24·2) 84·1% (22·4) 85·4% (24·6) 0·54
Exacerbations and quality of life
Annual exacerbation frequency* 4·2 (3·4) 2·6 (2·5) 2·7 (2·8) 0·0017
Hospital admission* 19 (35%) 29 (21%) 63 (23%) 0·12
SGRQ score 55·4 (21·9) 45·3 (23·7) 44·3 (21·9) 0·0069
LCQ score 12·7 (4·9) 14·4 (4·4) 14·3 (4·4) 0·029
HRCT score 4 (3–15) 3 (2–6) 3 (2–6) 0·0011
Body-mass index, kg/m² 26·9 (7·2) 25·8 (5·2) 25·8 (5·4) 0·43
Inﬂ ammatory markers
Myeloperoxidase (units per mL) 15·4 (24·3) 6·3 (11·7) 9·5 (16·1) 0·0022
Neutrophil elastase (units per mL) 27·0 (39·8) 14·9 (36·6) 13·9 (32·8) 0·038
Interleukin 8 (ng/mL) 48·5 (24·4) 45·3 (31·1) 38·0 (24·1) 0·0076
TNFα (pg/mL) 2718 (3089) 1383 (2022) 1458 (1968) 0·0003
Interleukin 1β (ng/mL) 3·1 (2·8) 2·1 (2·5) 2·5 (2·7) 0·015
Data are median (IQR), n (%), or mean (SD), unless otherwise stated. Data show results at baseline; data during 
prospective follow-up are presented elsewhere in the report. MBL=mannose-binding lectin. FEV1=forced expiratory 
volume in 1 s. FVC=forced vital capacity. SGRQ=St George's respiratory questionnaire. LCQ=Leicester cough 
questionnaire. HRCT=high-resolution CT. *In the year before the study.
Table 4: Baseline markers of severity in patients with MBL deﬁ ciency, according to genotype
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was in the non-deﬁ cient groups (table 4). Frequency of 
exacerbations did not diﬀ er between non-deﬁ cient 
groups. Patients with serum concentrations of less than 
200 ng/mL had more frequent exacerbations compared 
with those with higher MBL concentrations (table 5). Our 
secondary-care popu lation of patients with bronchiectasis 
had strikingly impaired of quality of life. St George’s 
respiratory questionnaire scores were higher for patients 
with low-expressing genotypes (table 4), but we noted no 
diﬀ er ences between non-deﬁ cient MBL genotypes 
(p=0·35). With the Leicester cough questionnaire, 
patients with low-expressing genotypes had severe cough 
symptoms compared with non-deﬁ cient genotypes 
(table 4); severity of cough symptoms did not diﬀ er 
between these non-deﬁ cient groups (p=0·49). Serum 
concentrations did not relate to St George’s respiratory 
questionnaire scores but were associated with Leicester 
cough questionnaire scores (table 5).
Patients with MBL deﬁ ciency were more likely to 
have exacerbations or be admitted to hospital during 
the 4 years of follow-up. Patients with low-expressing 
genotypes had a mean exacerbation rate of 2·7 per 
patient per year (SD 1·8), compared with patients with 
intermediate-expressing genotypes (mean 1·9 per pa-
tient per year [SD 1·2]) or high-expressing genotypes 
(mean 1·9 per patient per year [SD 1·3]; p<0·0001). The 
diﬀ erence in the mean incidence of exacerbations 
between patients with low-expressing genotypes and 
non-deﬁ cient genotypes was 0·72 per patient per year 
(95% CI 0·34–1·10). A greater proportion of patients 
with low-expressing genotypes were admitted to 
hospital on at least one occasion during follow-up 
(27 [49%] of 55 patients in the low-expressing group 
compared with 42 [31%] of 135 patients in the 
intermediate-expressing group and 87 [31%] of 
280 patients in the high-expressing group; p=0·032). 
Patients with serum MBL deﬁ ciency (<200 ng/mL 
cutoﬀ ) had an increased frequency of exacerbations 
(mean 2·6 [SD 1·7] for deﬁ ciency vs 1·8 [1·3] for non-
deﬁ ciency; p<0·0001) and an increased frequency of 
hospital admission during follow-up (38 [42%] vs 118 
[31%]; p=0·027). The increased frequency of 
exacerbations was also noted with a cutoﬀ  of 500 ng/mL 
(mean 2·1 [SD 1·6] for deﬁ ciency vs 1·8 [1·3] for non-
deﬁ ciency; p=0·044) but rates of hospital admission did 
not persist (49 [38%] vs 107 [31%]; p=0·15). Patients with 
low-expressing genotypes had higher rates of airway 
inﬂ ammation than did patients without this deﬁ ciency 
(table 4). These diﬀ erences were mainly attributable to 
increased bacterial loads in sputum for patients with 
low-expressing genotypes compared with non-deﬁ cient 
genotypes (mean log10 bacterial load 6·5 [SD 2·8] in the 
deﬁ cient group vs 5·1 [3·4] in the intermediate-ex-
pressing genotype group and 5·0 [3·3] in the high-
expressing genotype groups; p=0·014 by ANOVA).
As reported previously,24 MBL serum concentrations 
are largely genetically determined and we noted no 
signiﬁ cant variation in MBL serum concen trations at 
the start, middle, or end of the study (p>0·05 for all 
comparisons; ﬁ gure 2). In subanalyses, changes in 
serum MBL over time did not correlate with 
deteriorating lung function or changes in bacterial 
MBL deﬁ ciency serum cutoﬀ  
<500 ng/mL
MBL deﬁ ciency serum cutoﬀ  
<200 ng/mL
Deﬁ cient 
(n=128)
Non-deﬁ cient 
(n=342)
p value Deﬁ cient 
(n=88)
Non-deﬁ cient 
(n=382)
p value
Age, years 63 (53–72) 64 (52–72) 0·78 63 (56–71) 64 (52–72) 0·95
Bacteriological ﬁ ndings
Chronic colonisation 94 (73%) 218 (64%) 0·047 67 (76%) 245 (64%) 0·032
Haemophilus 
inﬂ uenzae
47 (37%) 94 (27%) 0·052 35 (40%) 106 (28%) 0·026
Pseudomonas 
aeruginosa
29 (23%) 39 (11%) 0·0020 22 (25%) 46 (12%) 0·0018
Pulmonary function
FEV1, percentage 
predicted
68·8% (25·5) 73·3% (24·7) 0·093 69·9% (26·1) 72·6% (24·7) 0·41
FVC, percentage 
predicted
84·8% (21·2) 85·3% (24·0) 0·85 81·5% (22·1) 85·5% (24·0) 0·60
Exacerbations and quality of life
Annual exacerbation 
frequency
3·3 (2·8) 2·7 (2·8) 0·062 3·5 (3·2) 2·7 (2·8) 0·032
Hospital admission 39 (30%) 72 (21%) 0·032 32 (36%) 79 (21%) 0·0018
SGRQ score 48·4 (24·1) 44·7 (22·5) 0·14 49·6 (21·1) 45·0 (23·2) 0·13
LCQ score 13·1 (4·8) 14·5 (4·4) 0·0050 13·2 (4·7) 14·4 (4·4) 0·021
HRCT score 3 (2–9) 3 (2–6) 0·46 4 (2–12) 3 (2–6) 0·036
Body-mass index, 
kg/m²
26·7 (5·8) 25·7 (5·3) 0·094 26·9 (6·0) 25·8 (5·3) 0·091
Data are median (IQR), mean (SD), or n (%), unless otherwise stated. MBL=mannose-binding lectin. FEV1=forced 
expiratory volume in 1 s. FVC=forced vital capacity. SGRQ=St George's respiratory questionnaire. LCQ=Leicester cough 
questionnaire. HRCT=high-resolution CT.
Table 5: Markers of severity in patients with MBL deﬁ ciency, according to serum concentration
Figure 2: MBL serum concentrations
Datapoints are means and bars are 95% CIs. Blood samples were obtained at 
recruitment (baseline), day 1 (onset of exacerbation), and day 14 (end of 
exacerbation), and repeated when clinically stable at least 3 months after 
exacerbation (stability). Increase in MBL during exacerbation was only diﬀ erent for 
the high-expressing haplotypes (p=0·01 by ANOVA). MBL=mannose-binding lectin. 
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colonisation (data not shown) but MBL serum 
concentrations were increased at the onset of 
exacerbations (ﬁ gure 2). We assessed 24 patients with 
high-expressing genotypes, 26 patients with 
intermediate-expressing genotypes, and 18 patients with 
MBL-deﬁ cient genotypes who attended for blood and 
sputum sampling at the onset of exacerbations and 
repeat measurement at completion of 14 days antibiotics. 
In the high-expressing MBL group, MBL concentrations 
increased by a mean of 27·3% at the start of the 
exacerbation (p=0·007). Although not statistically 
signiﬁ cant, we noted a similar pattern in the 
intermediate-expressing group (mean increase 20·2%; 
p=0·37). Patients with low-expressing genotypes 
(p=0·82) did not upregulate MBL serum concentrations 
during exacerbation (ﬁ gure 2).
42 deaths occurred during follow-up, with 25 (60%) 
of these deaths deemed to be related to bronchiectasis. 
In an exploratory analysis, we noted that eight (15%) 
deaths occurred in 55 patients with low-expressing 
genotypes, ten (7%) deaths occurred in 135 patients 
with inter mediate-expressing genotypes, and 24 (9%) 
deaths occurred in 280 patients with high-expressing 
genotypes. Figure 3 shows the Kaplan-Meier analysis 
of all-cause mortality. Mortality did not diﬀ er signi-
ﬁ cantly between groups (log-rank p=0·25). A Cox-
proportional hazard regression analysis adjusting for 
age, FEV1, bacterial colonisation, and radiological 
severity of bronchiectasis did not establish higher 
mortality in the low-expressing genotype group (hazard 
ratio 1·58, 95% CI 0·73–3·4; p=0·44). No increase in 
mortality was associated with serum MBL levels of less 
than 200 ng/mL (hazard ratio 1·43, 95% CI 0·65–3·12; 
p=0·37) and no increase in mortality associated with 
serum MBL levels of less than 500 ng/mL (1·07, 
0·54–2·12; p=0·84).
Discussion
To our knowledge, this study is the ﬁ rst to describe a 
genetic modiﬁ er of disease severity in non-cystic ﬁ brosis 
bronchiectasis. We showed that MBL deﬁ ciency (deﬁ ned 
by genotype) was related to severity of disease, including 
quality of life and frequency of exacerbations and 
admission to hospital (panel).
Deﬁ ciency of MBL arises from variants in exon-1 and 
in the promoter region of the MBL2 gene. Exon-1 alleles 
designated B, C, and D have a profound dominant eﬀ ect 
on MBL serum concentrations. Patients homozygous for 
exon-1 mutations or compound heterozygous for an 
exon-1 mutation and the X/Y promoter polymorphism 
have very low serum MBL concentrations, typically less 
than 200 ng/mL.5,12,16
Our study showed that these patients, with low serum 
MBL concentrations, have an increased frequency of 
chronic bacterial colonisation and an increased 
incidence of H inﬂ uenzae and P aeruginosa compared 
with patients with higher serum MBL concentrations. 
Compared with patients with non-deﬁ cient MBL 
expression, patients with low-expressing genotypes had 
severe bronchiectasis as assessed by radiological 
scoring, and an increased frequency of outpatient 
exacerbations and hospital admissions for severe 
exacerbations during 4 years of follow-up. These 
patients also had increased impairment in quality of 
life and worse cough severity as assessed by the 
Leicester cough questionnaire. Patients with low-
expressing genotypes had signiﬁ cantly higher measures 
of neutrophil mediated airway inﬂ ammation, primarily 
related to higher bacterial loads. Our study was not 
powered to assess mortality and larger multicentre 
studies are needed to address this outcome.
Despite our ﬁ nding of increased severity of disease in 
patients with MBL deﬁ ciency, measurements of FEV1 and 
FVC did not diﬀ er between MBL groups. This ﬁ nding 
might seem inconsistent, but adds to a growing body of 
Figure 3: Long-term prognosis in patients with bronchiectasis according to 
MBL genotype group (A) and mean reduction in percentage predicted 
forced expiratory volume in 1 s (B)
Error bars in (B) show standard error of the mean; p=0·3 for comparison 
between groups.
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literature suggesting that spirometric values are not as 
useful for prediction of outcome in non-cystic ﬁ brosis 
bronchiectasis as they are in cystic ﬁ brosis. For example, 
FEV1 was not identiﬁ ed as an independent predictor of 
outcome in a study of long-term survival in 
bronchiectasis,24 and other trials22,25 have shown FEV1 does 
not improve signiﬁ cantly in response to treatment in 
bronchiectasis.
Notably, we did not identify any evidence for an eﬀ ect 
of intermediate-expressing MBL genotypes on disease 
severity, with no signiﬁ cant diﬀ erences noted in these 
markers of disease severity between intermediate-
expressing and high-expressing MBL genotypes.
When we used deﬁ nitions of serum MBL deﬁ ciency 
determined a priori (serum concentration <500 ng/mL 
or <200 ng/mL), we noted a signiﬁ cant association 
between serum MBL and bacterial colonisation, 
hospital admis sion, exacerbations, and radiological 
severity. These diﬀ erences were, however, wholly 
attributable to the presence of patients with the most 
severe MBL deﬁ ciency in this group, because exclusion 
of patients with low-expressing MBL genotypes 
removed the association. We therefore conclude that 
patients with intermediate-expressing MBL genotypes 
are not at increased risk of severe disease. Our study 
suggests that genotype is the most useful method of 
deﬁ ning MBL deﬁ ciency, rather than serum levels, for 
future studies of MBL in bronchiectasis. Although 
serum levels are genetically determined, they can also 
be inﬂ uenced by hormones, drugs, and the acute phase 
response.28 We previously reported29 no diﬀ erences 
between patients with bronchiectasis and controls in 
serum MBL concentrations and have now conﬁ rmed 
these ﬁ ndings in a larger cohort. One other study30 
investigated the eﬀ ect of serum MBL on disease 
severity in 133 patients with non-cystic ﬁ brosis 
bronchiectasis. The study measured serum MBL con-
centrations but did not do genotyping, and reported no 
diﬀ erence in disease severity between patients with 
serum concentrations of less than 600 ng/mL 
compared with those with more than 600 ng/mL. 
Although the study30 was underpowered to show 
signiﬁ cant diﬀ erences, a subgroup analysis of 
13 patients suggested that serum concentrations of less 
than 100 ng/mL were associated with severe disease 
with more P aeruginosa and H inﬂ uenzae infections 
and a higher frequency of exacerbations. These results 
seem therefore to support the ﬁ ndings of our present 
study, showing that only patients with severe MBL 
deﬁ ciency have a worse phenotype. However, several 
diﬀ erences existed between MacFarlane and colleagues’ 
study30 and our own, including that their study obtained 
MBL measure ments for clinical reasons and therefore 
included a much higher frequency of patients colonised 
with P aeruginosa than is typically reported in the 
literature.
Several large studies have now conﬁ rmed a relation 
between low-expressing MBL genotypes and disease 
severity in cystic ﬁ brosis.14–16 Meta-analysis of studies16 in 
adults with cystic ﬁ brosis showed that MBL deﬁ ciency 
was associated with early acquisition of P aeruginosa, 
increased infections with B cepacia, and increased 
mortality. Notably, the largest studies suggest that the 
poor prognosis associated with variant MBL alleles is 
only evident in those with low-expressing MBL 
genotypes (YO/YO and XA/YO).14 The meta-analysis also 
reported no signiﬁ cant eﬀ ect on lung function or 
markers of cystic ﬁ brosis severity with the intermediate-
expression genotypes.16 This ﬁ nding sup ports the results 
of the present study that suggested poor prognosis is 
associated with the low-expressing geno types but that 
intermediate MBL expression is not associated with 
greater disease severity.
Evidence from studies of chronic obstructive pul-
monary disease suggests that MBL deﬁ ciency might 
predispose patients to exacerbations.27 Our study re-
cruited patients from a specialist bronchiectasis clinic 
and therefore few patients in our cohort had a 
diagnosis of chronic obstructive pulmonary disease. 
Panel: Research in context
Systematic review
We searched Pubmed, Embase, and Google scholar for articles published in any 
language between Jan 1, 1980, and Nov 30, 2012, with the search terms: 
“bronchiectasis”, “cystic ﬁ brosis”, or “CF” AND “mannose-binding lectin” OR 
“mannan-binding lectin” OR “MBL” OR “MBL2” OR “MBL-2”. This search updated a 
previous systematic review published in 2010.16 We identiﬁ ed two studies of 
mannose-binding lectin (MBL) in non-cystic ﬁ brosis bronchiectasis: one study25 that 
reported no diﬀ erence in MBL serum concentrations between patients and controls 
and another UK-based study of 133 patients that reported no diﬀ erence in disease 
severity between patients with serum concentrations of less than 600 ng/mL and 
those patients with serum concentrations of more than 600 ng/mL. We identiﬁ ed no 
genetic studies in non-cystic ﬁ brosis bronchiectasis. For cystic ﬁ brosis, meta-analysis of 
18 studies suggested that MBL-deﬁ cient genotypes were associated with younger age 
of onset of colonisation with Pseudomonas aeruginosa (1713 patients; mean diﬀ erence 
3·7 years [95% CI 2·1–5·3 years]; p<0·0001), colonisation with Burkholderia cepacia 
(odds ratio 3·5 [95% CI 1·1–10·5]; p=0·028), lower forced expiratory volume in 1 s in 
adults (mean diﬀ erence 19·7% [95% CI 10·8–28·0]; p<0·0001), and a higher risk of 
end-stage cystic ﬁ brosis (death or lung transplantation; odds ratio 2·4 [95% CI 1·1–5·2]; 
p=0·034).
Interpretation
Our study shows that MBL deﬁ ciency deﬁ ned by genotype is associated with increased 
severity of bronchiectasis as deﬁ ned by exacerbation frequency, hospital admission, 
radiological ﬁ ndings, and health-related quality of life. Patients with an MBL deﬁ ciency 
also had a higher frequency of colonisation with bacteria including Haemophilus 
inﬂ uenzae and P aeruginosa. After 4 years of follow-up, patients had more exacerbations 
and hospital admissions without signiﬁ cant association noted for survival or decline in 
lung function over time. MBL might be an important modiﬁ er of disease severity in 
non-CF bronchiectasis. This postulation should be conﬁ rmed in an independent 
cohort. Recent evidence that the antibiotic azithromycin, which is eﬀ ective in 
bronchiectasis,26 can reverse the basic defect associated with bronchiectasis27 might 
lead to a new pharmacogenetic approach to treatment of this disease.
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Bronchiectasis occurs commonly in patients with 
chronic obstructive pulmonary disease,31 so whether 
MBL deﬁ ciency also plays a part in chronic obstructive 
pulmonary disease and associated bronchiectasis will be 
important to understand.
The mechanism through which MBL predisposes to 
severe disease is not clear, although reports suggest that 
MBL binds P aeruginosa, S aureus, and B cepacia and 
other clinically relevant bacteria, leading to complement 
activation and enhanced clearance.6,7 MBL deﬁ ciency 
might therefore lead to deﬁ cient opsonophagocytosis; 
however, other mechanisms have also been proposed. 
MBL seems to be important in clearance of apoptotic 
cells, a key mechanism for the resolution of inﬂ am-
mation. Hodge and colleagues reported low concen-
trations of MBL in the airway of patients with chronic 
obstructive pulmonary disease and importantly, these 
low concentrations correlated with reduced apoptotic 
cell clearance.32
To our knowledge, our report is the largest study to 
examine genetic modiﬁ ers of disease severity in non-
cystic ﬁ brosis bronchiectasis.33,34 Strengths of the study 
included the relative absence of confounders such as 
long-term antibiotic and steroid use and current 
smoking. We included a broad spectrum of patients 
from individuals with very mild disease to those with 
very severe disease who had veriﬁ ed hospital admissions 
and exacerbations using electronic data to reduce bias. 
Our data are from a single centre in the UK and are not 
necessarily generalisable to other health-care settings. 
Ideally our ﬁ ndings should now be replicated in a large 
independent, multicentre cohort.
MBL deﬁ ciency is a recognised immunodeﬁ ciency, 
with clinical testing available in many centres and 
guideline recommendations suggesting such testing 
should be done for patients with suspected primary 
immunodeﬁ ciency.35 Identiﬁ cation of a group of patients 
at increased risk of exacerbations and poor outcome 
could be very useful to clinicians and we hope will 
stimulate further research to improve outcomes in 
bronchiectasis. Presently, few evidence-based treatments 
exist for bronchiectasis.1 MBL-replacement therapy has 
been developed and might form a new therapeutic 
avenue for diseases associated with MBL deﬁ ciency.36 Of 
more immediate clinical relevance to bronchiectasis, 
Hodge and colleagues showed that azithromycin could 
restore the failure of apoptotic-cell clearance associated 
with MBL deﬁ ciency, which raises the question of 
whether future trials should speciﬁ cally target long-term 
macrolide treatment for patients with MBL deﬁ ciency to 
improve outcome.25,32
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